Released May 8, 2020, before the open
10-Q filed May 8, 2020, 38 days after period end · 0001564590-20-023243
Q1 2020 · 10-Q
Revenue$169.00K$169.00K −95.6% vs Q1 2019−75.7% vs Q4 2019
Net Income-$23.30M-$23.30M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$1.22-$1.22 N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$22,821,000N/M
Operating Cash Flow-$23,329,000N/M
Free Cash Flowderived-$23,408,000N/M
Margins · derived
Operating margin-13503.6%−13353.9 pt vs Q1 2019
Net margin-13787.0%−13653.0 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $169.00K | $3.81M | $1.15M | $140.00K |
| Net Income | -$23.30M | -$5.10M | -$10.64M | -$5.88M |
| EPS Diluted | -$1.22 | -$0.29 | -$0.74 | -$21.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR